Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals, Inc.

Canaccord Genuity analyst Brian McNamara maintained a Buy rating on Central Garden Pet yesterday and set a price target of $53.00. The company’s sh...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$13.77	+3.22%	182.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$13.77	+3.2%	182.99K
3
4
5
6

ENTA

ENTA

Get Enanta Pharmaceuticals, Inc. Data in Excel

Get Enanta Pharmaceuticals, Inc. Data in Excel